The Study
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
This study gave some people a statin pill and others a sugar pill to see if the statin changed a blood marker linked to heart disease. It found that the statin group had a bigger drop in that marker. But it didn't watch to see if anyone had a heart attack — so we can't say for sure the pill prevents heart problems, just that it changed one thing in the blood.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study tested if a common cholesterol-lowering pill (rosuvastatin) could reduce inflammation in the blood vessels of people with HIV who are otherwise healthy on medication.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 572 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Lowering Lp-PLA2 may help prevent heart attacks in HIV patients, since this marker is linked to unstable artery plaques — even if other inflammation stays high.
- 2After 24 weeks, the drug lowered a blood vessel inflammation marker (Lp-PLA2) by 10% and LDL cholesterol by 28%, even though patients didn't have high cholesterol to begin with.
- 3It did not lower other inflammation markers like CRP or immune cell activation.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of infectious diseases
Year
2014
Authors
A. Eckard, Ying Jiang, S. Debanne, N. Funderburg, G. McComsey
Related Content
Claims (6)
In HIV-infected adults with normal cholesterol levels, taking 10 mg of rosuvastatin daily for 24 weeks lowers LDL cholesterol by about 28%.
HIV patients who previously had very low CD4+ T-cell counts experience a larger decrease in Lp-PLA2, a marker of vascular inflammation, after taking rosuvastatin compared to those with higher past CD4+ counts.
Taking 10 mg of rosuvastatin daily for 24 weeks lowers Lp-PLA2 levels by about 10% in HIV-positive adults with controlled virus and normal LDL cholesterol, even when LDL cholesterol does not change, showing a direct reduction in vascular inflammation.
In adults with HIV, taking rosuvastatin for 24 weeks does not lower levels of systemic inflammation markers like hsCRP and IL-6, but it does lower a marker specific to blood vessel inflammation.
In adults with HIV who are taking antiretroviral drugs, taking rosuvastatin for 24 weeks does not reduce the levels of CD38 and HLA-DR on CD8+ T cells, even though it lowers signs of blood vessel inflammation.
Statins do not correct the core metabolic problems, persistent inflammation, or insulin resistance that cause cardiovascular disease.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.